Biovail Corporation

Biovail Corporation

February 28, 2005 10:25 ET

Biovail Announces Fourth Quarter 2004, Year-End Earnings Release, Conference-Call Details


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: BIOVAIL CORPORATION

NYSE, TSX SYMBOL: BVF

FEBRUARY 28, 2005 - 10:25 ET

Biovail Announces Fourth Quarter 2004, Year-End
Earnings Release, Conference-Call Details

TORONTO--(CCNMatthews - Feb 28, 2005) -

Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that it will
host a conference call and Webcast on Thursday, March 10, 2005, at 8:30
a.m. EST, for company executives to discuss 2004 fourth-quarter and
year-end financial and operational results.

Following the discussion, Biovail executives will address inquiries from
investment analysts.

Biovail also announced that on March 10, the Company intends to issue,
and file shortly thereafter with regulators, a complete set of fully
audited financial statements, notes to the financial statements and
management's discussion and analysis of the statements.

A live Webcast of this call will be available through the Investor
Relations section of Biovail's Web site at www.biovail.com. To access
the call live, please dial 416-405-9310 (Toronto and International
callers) and 1-877-211-7911 (U.S. and Canada). Listeners are encouraged
to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7 p.m. EST on
Thursday, March 17, 2005, by dialing 416-695-5800 (Toronto and
International callers) and 1-800-408-3053 (U.S. and Canada), using
access code, 3140863.

About Biovail Corporation

Biovail Corporation is an international full-service pharmaceutical
company, engaged in the formulation, clinical testing, registration,
manufacture, sale and promotion of pharmaceutical products utilizing
advanced drug-delivery technologies.

For further information, please contact Ken Howling at 905-286-3000 or
send inquiries to ir@biovail.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform
Act of 1995

To the extent any statements made in this release contain information
that is not historical, these statements are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements on our current
expectations and projections about future events. Our actual results
could differ materially from those discussed in, or implied by, these
forward-looking statements. Forward-looking statements are identified by
words such as "believe", "anticipate", "expect", "intend", "plan",
"will", "may" and other similar expressions. In addition, any statements
that refer to expectations, projections or other characterizations of
future events or circumstances are forward-looking statements.
Forward-looking statements include, but are not necessarily limited to,
risks and uncertainties, including the difficulty of predicting U.S.
Food and Drug Administration ("FDA") and Canadian Therapeutic Products
Directorate ("TPD") approvals, acceptance and demand for new
pharmaceutical products, the impact of competitive products and pricing,
new product development and launch, reliance on key strategic alliances,
availability of raw materials and finished products, third parties, the
regulatory environment, fluctuations in operating results and other
risks detailed from time to time in the company's filings with the
Securities and Exchange Commission ("SEC") and the Ontario Securities
Commission ("OSC"). Biovail Corporation undertakes no obligation to
update or revise any forward-looking statement.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Biovail Corporation
    Kenneth G. Howling, 905-286-3000